Czech/SlovakiaCzech RepublicSlovakia

A2Z to begin reagent production

29.04.2009

Prague – A2Z Bio, the Czech subsidiary of UK-based Yorkshire Bioscience, is investing EUR100,000 at the CKD Prague Technological Innovation Centre to launch production of research reagents and services for the biotech R&D market. The company also announced it is hiring 5-6 experts plus administrative staff. Starting in September, A2Z Bio will begin manufacturing anti­bodies, oligonucleotides, synthetic genes and related services at the Prague site. “We will also offer the opportunity to outsource research to us,” explained

Slava Pavlovets, director of A2Z Bio.
“Biotechnology has a very promising future in the Czech Republic. The sector will be shaped primarily by smaller firms that nevertheless can offer leading technologies and unique know-how,” said Alexandra Rudyšarová, acting CEO of CzechInvest. According to the state promotional agency, about 10% of the countrys’ industry applications make use of biotechnologies.
A2Z Bio wants to sell products and services worth a250,000 in the first year of operations. “This is not just a one-off investment,” explained Pavlovets. “Our expansion to the Czech Republic is a long-term undertaking. We will invest much more in the Czech Republic.” A2Z Bio says it selected the Czech site because it offers an efficient connection to the whole of Europe.
“Our choices came down to southern Germany and the Czech Republic,” Pavlovets says. “In the end we decided for the Czech Republic because we will get much higher quality here for the same price.”

Czech/SlovakiaCzech RepublicSlovakia

11.07.2007

Prague/Foster City – An oligonucleotide analogon, originally developed at the Institute of Organic Chemistry and Biochemistry (IOCB) at the Czech Academy of Sciences in Prague, has entered clinical testing as treatment for...

Czech/SlovakiaCzech RepublicSlovakia

17.05.2007

Prague/Leuven – The Czech Republic is lagging behind in applying the ten year-old European convention on Human rights and biomedicine, according to a new report from EuroGentest, an EU-funded Network of Excellence, which assesses...

Czech/SlovakiaCzech RepublicSlovakia

21.11.2006

BIOTEC 2006, the first international biotechnology conference and exhibition in Eastern Europe, held at the end of October, staged the official inauguration ceremony of the International Clinical Research Center (ICRC). The...

Czech/SlovakiaCzech RepublicSlovakia

16.09.2006

In order to keep track of developments and to promote network-creation, for both domestic-domestic and domestic-foreign cooperations the South Moravian Innovation Centre, Brno, has conducted the Czech Republic’s first...

Czech/SlovakiaCzech RepublicSlovakia

21.07.2006

Bratislava – In late-April, the Slovak government authorized field trials with genetically modified MON 810 maize at three undisclosed locations. The total area of the field trials is approximately 30 hectares. Although Slovakia...

Czech/SlovakiaCzech RepublicSlovakia

21.07.2006

Pruhonice – Biomass production is a promising alternative for the Czech Republic’s agricultural sector. Biomass could cover the annual domestic bio-energy demand of 250 PJ (predicted for 2030), and could be exported as bio-fuels...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2006

Prague - The French pharma giant Sanofi-Aventis S.A. strengthened its generics business in Central and Eastern Europe (CEE) with a participation in the Czech generics producer Zentiva a.s. According to Sanofi-Aventis, the company...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2006

Brno - The International Clinical Research Center (ICRC) in Brno, will collaborate with the renowned Mayo Clinic in Rochester, MN, to establish a clinical and research education center that meets the challenges of 21st-century...

Czech/SlovakiaCzech RepublicSlovakia

17.03.2006

Humpolec - A product derived from genetically modified potatos with altered starch composition poses no threat to human health, according to a European Food Safety Authority (EFSA) panel ruling.BASF Plant Science's GM potato,...

Czech/SlovakiaCzech RepublicSlovakia

17.03.2006

Brno - Spinning out a company in the Czech Republic is far from common. That has not stopped Jiri Damborsky, who led a protein engineering group at Masaryk University, Brno, from founding his own company, Enantis. His firm will...

Displaying results 31 to 40 out of 70

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/3/article/a2z-to-begin-reagent-production.html

Events

All Events

Stock list

All quotes

TOP

  • BIOINVENT INTERNATIONAL AB (S)3.10 SEK9.15%
  • Allergy Therapeutics (UK)19.12 GBP6.94%
  • PHARMING (NL)0.48 EUR6.67%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • CHRONTECH PHARMA (S)0.07 SEK-12.50%

TOP

  • WILEX (D)3.15 EUR314.5%
  • SANTHERA (CH)68.55 CHF90.4%
  • ADDEX (CH)4.08 CHF82.1%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.83 EUR-26.8%
  • PROSENSA (NL)9.48 USD-25.2%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP729.1%
  • PAION (D)2.79 EUR316.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • PROSENSA (NL)9.48 USD-68.0%

No liability assumed, Date: 25.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products